GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The Product will be manufactured at the company's facility in Bengaluru
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Subscribe To Our Newsletter & Stay Updated